181 results about "Acute renal failures" patented technology

The invention relates to a double-stranded compound, preferably an oligoribonucleotide, which down-regulates the expression of a human p53 gene. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating a patient suffering from alopecia or acute renal failure or other diseases comprising administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient. The alopecia may be induced by chemotherapy or radiotherapy, and the patient may be suffering from cancer, in particular breast cancer.

The present invention relates to methods of diagnosing, predicting and monitoring kidney diseases, including acute renal failure, renal tubular interstitial disease and glomerulonephritis. In particular, the present invention relates to the detection, prediction and monitoring of kidney diseases by detection of CXCR3 and CCL chemokines in urine. The present invention further relates to methods and compositions for assessing the efficacy of agents and interventions used to treat kidney diseases.

The invention relates to a double-stranded compound, preferably an oligoribonucleotide, which down-regulates the expression of a human p53 gene. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating a patient suffering from acute renal failure or other kidney diseases comprising administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient.

A bifunctional hormone exhibiting an alpha-MSH activity and a natriuretic peptide activity is described. The bifunctional hormone comprises for example a first domain having alpha-MSH related hormonal activity covalently linked to a second domain having natriuretic peptide related hormonal activity. The bifunctional hormone of the present invention is useful for example for the prevention and / or treatment of renal related diseases or conditions, such as acute renal failure (ARF) or acute kidney injury (AKI).

The present invention relates to novel compounds of 2-propene-1-one series, of general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them, wherein R5, R6, Q and Y are as defined in the specification. The present invention also relates to a process for preparing such compounds, compositions containing such compounds, and use of such compound and composition in medicine. The compounds of the general formula (I) induce HSP-70 and are useful for the treatment of diseases accompanying pathological stress in a living mammalian organism, including a human being, such as stroke, myocardial infarction, inflammatory disorder, hepatotoxicity, sepsis, diseases of viral origin, allograft rejection, tumourous diseases, gastric mucosal damage, brain haemorrhage, endothelial dysfunctions, diabetic complications, neuro-degenerative diseases, post-traumatic neuronal damage, acute renal failure, glaucoma and aging related skin degeneration.

A method for distinguishing between kidney dysfunctions in a mammal, including pre-renal azotemia, an acute renal injury that may progress to acute renal failure, and chronic kidney disease, using a urinary or circulating NGAL assay result that is compared to a predetermined NGAL cutoff level, and a single serum or plasma creatinine measurement. Typically the single creatinine measurement cannot distinguish acute renal injury from chronic kidney disease or pre-renal azotemia, a single measurement of urinary NGAL, combined with the single serum or plasma creatinine measurement, has sufficient sensitivity and specificity to distinguish acute renal injury from normal function, prerenal azotemia, and chronic kidney disease and predicts poor inpatient outcomes. Patients admitted to the emergency department of the hospital with any of acute kidney injury, prerenal azotemia, chronic kidney disease, or even normal kidney function, can be evaluated based on the single measurements of urinary or circulating NGAL, and serum or plasma creatinine. Urinary NGAL level is highly predictive of clinical outcomes, including nephrology consultation, dialysis, and admission to the intensive care unit.

Methods for the treatment of acute renal failure, multi-organ failure, early dysfunction of kidney transplant, chronic renal failure, organ dysfunction, and wound healing are provided. The methods include delivering a therapeutic amount of hematopoietic stem cells, non-hematopoietic, mesenchymal stem cells, hemangioblasts, and pre-differentiated cells to a patient in need thereof.

The present invention relates to methods of diagnosing, predicting and monitoring kidney diseases, including acute renal failure, renal tubular interstitial disease and glomerulonephritis. In particular, the present invention relates to the detection, prediction and monitoring of kidney diseases by detection of CXCR3 and CCL chemokines in urine. The present invention further relates to methods and compositions for assessing the efficacy of agents and interventions used to treat kidney diseases.

The invention relates to the fields of organic synthesis and medicinal chemistry and in particular relates to an O-(piperidyl)ethyl derivative of cleistanone, a preparation method and application of the O-(piperidyl)ethyl derivative to preparation of medicines for resisting acute renal failure (ARF). The invention synthesizes a new O-(piperidyl)ethyl derivative of cleistanone and discloses the preparation method of the O-(piperidyl)ethyl derivative. Pharmacology experiments show that the O-(piperidyl)ethyl derivative of cleistanone has the function of resisting ARF and has the value of developing the medicines for resisting ARF.

The invention discloses a traditional Chinese preparation for treating acute renal failure. The traditional Chinese preparation is prepared by selecting bulk drugs respectively in parts by weight as follows: 20-30 g of rhubarb, 10-20 g of cassia twig, 10-20 g of poria cocos, 10-20 g of rhizoma alismatis,10-20 g of rhizoma imperatae, 10-20 g of buffalo horn, 10-20 g of Cirsium japonicum, 10-20 g of safflower, 10-20 g of figwort roots, 8-15 g of tetrapanax papyriferus, 8-12 g of peach kernel, 8-12 g of antelope horn powder, 8-12 g of white mulberry root-bark, 8-12 g of semen lepidii, 8-12 g of polygonum aviculare and 8-12 g of dianthus superbus. All the drugs are compatible to achieve tonification and purgation in combination, and together play the function of reinforcing Qi and nourishing blood, activating blood circulation to dissipate blood stasis, clearing heat and detoxifying, achieving cathartic purpose, and alleviating water retention and freeing strangury. The traditional Chinese preparation is obvious in curative effect, free of negative or side effects and high in cure rate when used for treating acute renal failure, requires a short time for recovering renal function normality, achieves low probability of recurrence after curing and is worthy of clinical popularization and application.

The invention relates to the use of a group of Chinese medicinal compositions in treating acute kidney failure and / or enhancing immunity, wherein the medicinal composition comprises the following raw materials (by weight portion): rhizome of Sichuan lovage 15-200 weight parts, astragalus root 40-450 weight parts, Chinese angelica root 20-220 weight parts, epimedium 15-185 weight parts, dried rehmannia root 15-205 weight parts, alisol 15-185 weight parts and poria cocos wolf 15-185 weight parts.